 | |
| Clinical data | |
|---|---|
| Other names | ASC-J9; GO-Y025 |
| Routes of administration | Topical |
| Drug class | Nonsteroidal antiandrogen; Selective androgen receptor degrader |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H24O6 |
| Molar mass | 396.439 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dimethylcurcumin (development code ASC-J9) is a nonsteroidal antiandrogen and a synthetic curcuminoid which is under development by AndroScience Corporation as a topical medication for the treatment of acne vulgaris. [1] [2] It has also been under investigation for the treatment of male pattern hair loss, spinal muscular atrophy, and wounds, but no development has been reported for these indications. [1] There has been interest in the drug for the potential treatment of prostate cancer as well. [2] [3] As of 2017, it is in phase II clinical trials for acne vulgaris. [1]
Dimethylcurcumin is an androgen receptor (AR) inhibitor and shows strong and specific antiandrogenic activity in vitro (e.g., against LNCaP cell growth) at sufficiently high concentrations. [3] However, its mechanism of action and effects differ from those of conventional antiandrogens; it is not an antagonist of the AR and instead appears to act as a selective degradation enhancer (SARD) of certain subpopulations of the AR, for instance those present in the prostate gland. [1] [3] [2]